SASCM guideline for daptomycin use in South Africa – 2017 update

References

• Dortet L, Anguel N, Fortineau N, et al. In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis. Int J Infect Dis: IJID: Official Publication of the International Society for Infectious Diseases. 2013;17(11):e1076–7.10.1016/j.ijid.2013.02.019
   PubMed Web of Science ®Google Scholar
• Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26(4):759–80.10.1128/CMR.00030-13
   PubMed Web of Science ®Google Scholar
• CLSI. Performace standards for antimicrobial susceptibility testing: CLSI supplement M100S. 26th ed. Wayne: Clinical and Laboratory Standards Institute; 2016.
   Google Scholar
• EUCAST. The European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Available from: http://www.eucast.org2016
   Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005–2012). Int J Antimicrob Agents. 2014;43(5):465–9.10.1016/j.ijantimicag.2014.01.018
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ansaldi F, De Florentiis D, et al. Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience Intensive Care Med. 2015;41(11):2026–8.10.1007/s00134-015-4021-9
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, VanPraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–52.10.1086/jid.2005.191.issue-12
   PubMed Web of Science ®Google Scholar
• Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):202–10.10.1016/j.ijantimicag.2013.05.005
   PubMed Web of Science ®Google Scholar
• Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003;47(5):1598–603.10.1128/AAC.47.5.1598-1603.2003
   PubMed Web of Science ®Google Scholar
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–8.10.1128/AAC.48.1.63-68.2004
   PubMed Web of Science ®Google Scholar
• Soon RL, Turner SJ, Forrest A, et al. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. Int J Antimicrob Agents. 2013;42(1):53–8.10.1016/j.ijantimicag.2013.02.009
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.10.1093/cid/cir034
   PubMed Web of Science ®Google Scholar
• EUCAST. Guidance document on use of daptomycin to treat enterococcal endocarditis. [cited 2016 Sep 24]. Available from http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/EUCAST_daptomycin_guidance_note_20160924.pdf.
   Google Scholar
• van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis: Official Publication of the European Society of Clinical Microbiology. 2011;30(5):603–10.10.1007/s10096-010-1128-3
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.10.1056/NEJMoa053783
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically Ill patients with methicillin-resistant staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568–76.10.1093/cid/cit582
   PubMed Web of Science ®Google Scholar
• Wu G, Abraham T, Rapp J, et al. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents. 2011;38(3):192–6.10.1016/j.ijantimicag.2011.03.006
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicco E, Ginocchio F, et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36(5):459–61.10.1016/j.ijantimicag.2010.07.011
   PubMed Web of Science ®Google Scholar
• Moise PA, Hershberger E, Amodio-Groton MI, et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43(7–8):1211–9.10.1345/aph.1M085
   PubMed Web of Science ®Google Scholar
• D’Avolio A, Pensi D, Baietto L, et al. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically Ill patients. Drugs. 2016;76(12):1161–74.10.1007/s40265-016-0610-3
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Parrella A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016;48(1):61–8.10.1016/j.ijantimicag.2016.04.022
   PubMed Web of Science ®Google Scholar
• Seaton RA, Menichetti F, Dalekos G, et al. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the european cubicin((R)) outcomes registry and experience. Adv Ther. 2015;32(12):1192–205.10.1007/s12325-015-0267-4
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–83.10.1093/cid/ciu027
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.10.1016/S1473-3099(14)70036-2
   PubMed Web of Science ®Google Scholar